Left Ventricular SGLT1 Protein Expression Correlates with the Extent of Myocardial Nitro-Oxidative Stress in Rats with Pressure and Volume Overload-Induced Heart Failure
Overview
Authors
Affiliations
Myocardial sodium-glucose cotransporter 1 (SGLT1) has been shown to be upregulated in humans with heart failure (HF) with or without diabetes. In vitro studies have linked SGLT1 to increased nitro-oxidative stress in cardiomyocytes. We aimed to assess the relation between left ventricular (LV) SGLT1 expression and the extent of nitro-oxidative stress in two non-diabetic rat models of chronic heart failure (HF) evoked by either pressure (TAC, = 12) or volume overload (ACF, = 12). Sham-operated animals (Sham-T and Sham-A, both = 12) served as controls. Both TAC and ACF induced characteristic LV structural and functional remodeling. Western blotting revealed that LV SGLT1 protein expression was significantly upregulated in both HF models (both < 0.01), whereas the phosphorylation of ERK1/2 was decreased only in ACF; AMPKα activity was significantly reduced in both models. The protein expression of the Nox4 NADPH oxidase isoform was increased in both TAC and ACF compared with respective controls (both < 0.01), showing a strong positive correlation with SGLT1 expression ( = 0.855, < 0.001; and = 0.798, = 0.001, respectively). Furthermore, SGLT1 protein expression positively correlated with the extent of myocardial nitro-oxidative stress in failing hearts assessed by 3-nitrotyrosin ( = 0.818, = 0.006) and 4-hydroxy-2-nonenal ( = 0.733, = 0.020) immunostaining. Therefore, LV SGLT1 protein expression was upregulated irrespective of the nature of chronic hemodynamic overload, and correlated significantly with the expression of Nox4 and with the level of myocardial nitro-oxidative stress, suggesting a pathophysiological role of SGLT1 in HF.
SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms.
Chen Y, Zhu F, Zhou R Front Cardiovasc Med. 2024; 11:1494882.
PMID: 39717441 PMC: 11663900. DOI: 10.3389/fcvm.2024.1494882.
Ionica L, Linta A, Batrin A, Hancu I, Lolescu B, Danila M Int J Mol Sci. 2024; 25(14).
PMID: 39062954 PMC: 11277154. DOI: 10.3390/ijms25147711.
Pan L, Xu Z, Wen M, Li M, Lyu D, Xiao H Chin Med. 2024; 19(1):82.
PMID: 38862959 PMC: 11165817. DOI: 10.1186/s13020-024-00959-1.
SGLT1: A Potential Drug Target for Cardiovascular Disease.
Zhao M, Li N, Zhou H Drug Des Devel Ther. 2023; 17:2011-2023.
PMID: 37435096 PMC: 10332373. DOI: 10.2147/DDDT.S418321.
Shi X, Dorsey A, Qiu H Antioxidants (Basel). 2022; 11(5).
PMID: 35624741 PMC: 9137593. DOI: 10.3390/antiox11050877.